Integrative Oncogenomics of Multiple Myeloma
多发性骨髓瘤的综合肿瘤基因组学
基本信息
- 批准号:8326575
- 负责人:
- 金额:$ 199.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-01 至 2016-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAutomobile DrivingAwarenessBasic ScienceBehaviorBioinformaticsBiologicalBiological MarkersBone MarrowBone Marrow CellsBortezomibCell CommunicationCellsClinicalClinical ResearchClinical TrialsCollaborationsCombined Modality TherapyCommunicationDNADNA Sequencing FacilityDevelopmentDiseaseDisease OutcomeDisease ProgressionDoseDrug resistanceEnrollmentEventEvolutionGeneticGenomeGenomic InstabilityGenomicsGoalsGrowthHigh-Dose Chemotherapy with Autologous Stem Cell TransplantIn VitroIn complete remissionIndividualInstitutesInternationalInvestigationLeadLesionMolecularMolecular GeneticsMultiple MyelomaNewly DiagnosedOutcomePathogenesisPathway interactionsPatientsPrevalenceRefractoryRelapseResearchResearch PersonnelRoleSamplingStromal CellsSubgroupTechnologyTherapeuticTherapeutic AgentsTissuesTranslatingTransplantationUnited StatesValidationbench to bedsidecancer genomicscell growthclinically relevantclinically significantcollaborative trialcytotoxicitydrug discoverygenetic analysisgenome sequencingimprovedin vivoin vivo Modellenalidomidemalignant phenotypeneoplastic cellnew therapeutic targetnext generationnoveloutcome forecastpre-clinicalpreclinical studypreventprognosticprogramsresponsetherapy development
项目摘要
Our myeloma research group, which has developed number of new targets and novel therapies (DFCI), will partner with the world leaders in cooperative clinical and transplantation trials in MM (IFM) to pursue collaborative translational investigation. We will couple combination novel therapies with high dose therapy and transplantation and then delineate genomic and molecular correlates of clinical and biological outcomes. Project 1 will focus on defining the durability of responses to novel combination therapy on the one hand, and the additional value of high dose therapy on the other, by enrolling 1000 newly diagnosed patients between IFM and DFCI. This trial will provide 1000 samples from newly diagnosed and uniformly treated patients to comprehensively characterize the MM genome and epigenome, to define molecular events driving development and progression of MM (Project 2), as well as to identify novel therapeutic targets (Project 3), biomarkers, and preventative strategies (Project 4). In these collaborative studies the Sanger Institute in UK, with whole genome sequencing capabilities, along with research teams from DFCI and IFM, will perform molecular genetic analysis of patient samples and delineate patient subgroups most likely to respond and achieve prolonged survival (Projects 2 and 4). The clinically relevant novel targets identified using these high throughput genomic technologies will be validated and novel targeted therapies developed in Project 3. Project 4 will further analyze evolution of genomic changes at relapse and their clinical significance, as well as devise strategies to prevent genomic instability. These 4 projects will be supported by Administrative and Communication Core (A), Clinical and Tissue Core (B); Genomics Core (C); Genomic Sequencing Core (0), and Biostatistical and Bioinformatics Core (E). This unique collaborative effort will define a new treatment paradigm for this presently incurable disease.
我们的骨髓瘤研究小组已经开发了许多新靶点和新疗法 (DFCI),将与多发性骨髓瘤合作临床和移植试验 (IFM) 的世界领先者合作,开展合作转化研究。我们将联合新疗法与高剂量疗法和移植相结合,然后描绘临床和生物学结果的基因组和分子相关性。项目 1 将重点关注通过在 IFM 和 DFCI 之间招募 1000 名新诊断患者,一方面确定新型联合疗法反应的持久性,另一方面确定高剂量疗法的附加价值。该试验将提供来自新诊断和统一治疗的患者的 1000 个样本,以全面表征 MM 基因组和表观基因组,定义驱动 MM 发生和进展的分子事件(项目 2),并确定新的治疗靶点(项目 3)、生物标志物和预防策略(项目 4)。在这些合作研究中,拥有全基因组测序能力的英国桑格研究所将与 DFCI 和 IFM 的研究团队一起,对患者样本进行分子遗传学分析,并确定最有可能做出反应并实现延长生存期的患者亚组(项目 2 和 4)。使用这些高通量基因组技术确定的临床相关新靶标将在项目 3 中得到验证并开发新的靶向疗法。项目 4 将进一步分析复发时基因组变化的演变及其临床意义,并制定预防基因组不稳定的策略。这4个项目将得到行政和沟通核心(A)、临床和组织核心(B)的支持;基因组学核心(C);基因组测序核心 (0) 和生物统计和生物信息学核心 (E)。这种独特的合作努力将为这种目前无法治愈的疾病定义一种新的治疗模式。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nikhil C. Munshi其他文献
Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia.
硼替佐米和利妥昔单抗联合治疗复发和/或难治性华氏巨球蛋白血症的 II 期试验。
- DOI:
- 发表时间:
2008 - 期刊:
- 影响因子:45.3
- 作者:
I. Ghobrial;J. Matous;S. Padmanabhan;A. Badros;R. Schlossman;S. Chuma;R. Leduc;Marybeth Nelson;Kelly O’Connor;A. Sam;B. Harris;J. Soumerai;D. Warren;A. Birner;Nikhil C. Munshi;S. Treon;K. Anderson;P. Richardson - 通讯作者:
P. Richardson
A TCR-like CAR T Cell Therapy for the Treatment of MZB1 Positive Multiple Myeloma and Other B-Cell Malignancies
- DOI:
10.1182/blood-2024-208607 - 发表时间:
2024-11-05 - 期刊:
- 影响因子:
- 作者:
Elena Maroto Martin;Yingjie Zhao;Sara Mangesh Kolhatkar;Roberto Garcia-Vicente;Mubin Tarannum;Mehmet K. Samur;Mariateresa Fulciniti;Rizwan Romee;Jianzhu Chen;Nikhil C. Munshi - 通讯作者:
Nikhil C. Munshi
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial
- DOI:
10.1016/j.leukres.2023.107074 - 发表时间:
2023-06-01 - 期刊:
- 影响因子:
- 作者:
Michel Delforge;Paula Rodríguez Otero;Nina Shah;Olga Moshkovich;Julia Braverman;Devender S. Dhanda;Sally Lanar;Jennifer Devlen;Matthew Miera;Heather Gerould;Timothy B. Campbell;Nikhil C. Munshi - 通讯作者:
Nikhil C. Munshi
OAB-033: Loss-of-function of GABARAP drives tumor resistance to bortezomib-induced immunogenic cell death in multiple myeloma
- DOI:
10.1016/s2152-2650(21)02107-8 - 发表时间:
2021-10-01 - 期刊:
- 影响因子:
- 作者:
Annamaria Gulla;Eugenio Morelli;Mehmet K Samur;Cirino Botta;Megan Johnstone;Giada Bianchi;Mariateresa Fulciniti;Leona Yamamoto;Rao Prabhala;Kenneth Wen;Paul G. Richardson;Yu-Tzu Tai;Dharminder Chauhan;Teru Hideshima;Nikhil C. Munshi;Kenneth Anderson - 通讯作者:
Kenneth Anderson
P-057: A helicase “ASCC3” is coupled to FEN1-mediated genomic instability and cancer cell proliferation
- DOI:
10.1016/s2152-2650(21)02191-1 - 发表时间:
2021-10-01 - 期刊:
- 影响因子:
- 作者:
Chengcheng Liao;Shidai Mu;Jiangning Zhao;Subodh Kumar;Leutz Buon;Srikanth Talluri;Mehmet K Samur;Masood Shammas;Nikhil C. Munshi - 通讯作者:
Nikhil C. Munshi
Nikhil C. Munshi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nikhil C. Munshi', 18)}}的其他基金
ShEEP request for next generation sequencing system
ShEEP 请求下一代测序系统
- 批准号:
9906671 - 财政年份:2019
- 资助金额:
$ 199.93万 - 项目类别:
ShEEP Request for BD FACSAria Fusion Cell Sorting Flow Cytometer
ShEEP 请求 BD FACSAria 融合细胞分选流式细胞仪
- 批准号:
9361304 - 财政年份:2017
- 资助金额:
$ 199.93万 - 项目类别:
MOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSE
分子调控增强抗骨髓瘤反应
- 批准号:
8597935 - 财政年份:2012
- 资助金额:
$ 199.93万 - 项目类别:
Molecular Manipulation to Enhance Anti-Myeloma Response
分子操作增强抗骨髓瘤反应
- 批准号:
10486218 - 财政年份:2012
- 资助金额:
$ 199.93万 - 项目类别:
MOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSE
分子调控增强抗骨髓瘤反应
- 批准号:
8963449 - 财政年份:2012
- 资助金额:
$ 199.93万 - 项目类别:
MOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSE
分子调控增强抗骨髓瘤反应
- 批准号:
8332546 - 财政年份:2012
- 资助金额:
$ 199.93万 - 项目类别:
Integrative Oncogenomics of Multiple Myeloma
多发性骨髓瘤的综合肿瘤基因组学
- 批准号:
10226185 - 财政年份:2011
- 资助金额:
$ 199.93万 - 项目类别:
Targeting Genomic Instability and Evolution in Myeloma
针对骨髓瘤的基因组不稳定性和进化
- 批准号:
8066222 - 财政年份:2011
- 资助金额:
$ 199.93万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 199.93万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 199.93万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 199.93万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 199.93万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 199.93万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 199.93万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 199.93万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 199.93万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 199.93万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 199.93万 - 项目类别:
Grant-in-Aid for Early-Career Scientists